OncoGenex Pharmaceuticals (NASDAQ:ACHV) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Monday.

Shares of OncoGenex Pharmaceuticals (NASDAQ ACHV) traded up $0.02 on Monday, hitting $1.31. 83,787 shares of the stock were exchanged, compared to its average volume of 85,807. OncoGenex Pharmaceuticals has a 12-month low of $1.26 and a 12-month high of $10.23.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.90) EPS for the quarter.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/04/valuengine-upgrades-oncogenex-pharmaceuticals-achv-to-sell.html.

About OncoGenex Pharmaceuticals

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.